Global Gout Therapeutics Market Size study, by Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), by Disease Condition (Acute Gout, Chronic Gout), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Global Gout Therapeutics Market Size study, by Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), by Disease Condition (Acute Gout, Chronic Gout), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Regional Forecasts 2022-2032

Global Gout Therapeutics Market is valued approximately at USD 2.65 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.25% over the forecast period 2024-2032. Gout, an inflammatory arthritis condition resulting from the deposition of monosodium urate crystals in joints and tissues, is characterized by severe pain, swelling, and redness, often affecting the big toe. The market for gout therapeutics is experiencing significant growth, driven by various factors including the increasing prevalence of gout worldwide, advancements in research and development, and growing awareness of early diagnosis and management of the condition.

The rising prevalence of gout is particularly notable in developed countries, attributed to aging populations, sedentary lifestyles, unhealthy diets, and the prevalence of obesity and hypertension. Continuous R&D efforts focused on developing innovative and effective gout therapeutics are further propelling market growth. Pharmaceutical companies are actively working on novel drug formulations, targeted therapies, and regenerative medicine approaches to address the unmet needs of gout patients. This includes new medications targeting specific pathways involved in gout pathogenesis and exploring biologics and gene therapies.

North America held the largest share of the global gout therapeutics market in 2021 and is projected to remain highly lucrative during the forecast period. The region's growth is driven by the high incidence of gout and associated comorbidities in the U.S., where gout is the most common inflammatory arthritis. Studies indicate that more than nine million Americans suffer from gout, with a significant portion undergoing oral urate-lowering therapies. Meanwhile, the Asia Pacific region is expected to witness rapid market growth from 2022 to 2031, spurred by increasing incidence and prevalence of gout, coupled with heightened research and development activities in gout diagnosis and treatment.

Major market players included in this report are:

Takeda Pharmaceutical Company Ltd.

Novartis AG

Regeneron Pharmaceuticals Inc.

AstraZeneca plc

Horizon Therapeutics plc

Merck & Co. Inc.

Teijin Pharma Ltd.

GlaxoSmithKline, Plc.

Zydus Group

Takeda Pharmaceuticals

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
• NSAIDs
• Corticosteroids
• Colchicine
• Urate-Lowering Agents
• Others

By Disease Condition:
• Acute Gout
• Chronic Gout

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico
• RoLA

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.